BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28987645)

  • 1. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
    Jain RS; Khan I; Kandelwal K; Desai T
    Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
    Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
    J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
    Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
    AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
    Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
    Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
    Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
    Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination.
    Pervin I; Ramanathan S; Cappelen-Smith C; Vucic S; Reddel SW; Hardy TA
    Mult Scler Relat Disord; 2024 Feb; 82():105408. PubMed ID: 38219394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
    Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmí I; Vivancos J
    J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology.
    Kobayashi M; Shimizu Y; Shibata N; Uchiyama S
    J Neurol; 2014 Oct; 261(10):1902-10. PubMed ID: 25034274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of oligoclonal IgG bands in Japanese clinically isolated syndrome converting to clinically definite multiple sclerosis.
    Kinoshita M; Daifu M; Tanaka K; Tanaka M
    J Neuroimmunol; 2017 Jun; 307():1-6. PubMed ID: 28495130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.
    Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK
    Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
    Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
    Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional and advanced magnetic resonance imaging in tumefactive demyelination.
    Saini J; Chatterjee S; Thomas B; Kesavadas C
    Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
    Di Gregorio M; Torri Clerici VLA; Fenu G; Gaetani L; Gallo A; Cavalla P; Ragonese P; Annovazzi P; Gajofatto A; Prosperini L; Landi D; Nicoletti CG; Di Carmine C; Totaro R; Nociti V; De Fino C; Ferraro D; Tomassini V; Tortorella C; Righini I; Amato MP; Manni A; Paolicelli D; Iaffaldano P; Lanzillo R; Moccia M; Buttari F; Fantozzi R; Cerqua R; Zagaglia S; Farina D; De Luca G; Buscarinu MC; Pinardi F; Cocco E; Gasperini C; Solaro CM; Di Filippo M
    Eur J Neurol; 2021 Apr; 28(4):1299-1307. PubMed ID: 33305459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of pediatric multiple sclerosis presenting with a tumefactive demyelinating lesion].
    Majima H; Ito T; Koyama N
    Rinsho Shinkeigaku; 2017 Feb; 57(2):88-91. PubMed ID: 28132974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.
    Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P
    J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
    Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
    Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
    Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging.
    Enzinger C; Strasser-Fuchs S; Ropele S; Kapeller P; Kleinert R; Fazekas F
    Mult Scler; 2005 Apr; 11(2):135-9. PubMed ID: 15794384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroimaging and clinicopathological differences between tumefactive demyelinating lesions and sentinel lesions of primary central nervous system lymphoma.
    Sun C; Han J; Lin Y; Qi X; Li C; Liu J; Qiu F
    Front Immunol; 2022; 13():986473. PubMed ID: 36059526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
    Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
    Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.